Ken Griffin Nevro Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.71 - $10.1 $109,272 - $234,320	23,200 Added 86.89%	49,900 $278,000
Q2 2024 Aug 14, 2024	SELL	$7.96 - $13.59 $15,124 - $25,821	-1,900 Reduced 6.64%	26,700 $224,000
Q1 2024 May 15, 2024	SELL	$13.56 - $20.78 $233,232 - $357,416	-17,200 Reduced 37.55%	28,600 $412,000
Q4 2023 Feb 14, 2024	SELL	$14.18 - $22.31 $168,742 - $265,489	-11,900 Reduced 20.62%	45,800 $985,000
Q3 2023 Nov 14, 2023	SELL	$18.22 - $25.85 $643,166 - $912,505	-35,300 Reduced 37.96%	57,700 $1.11 Million
Q2 2023 Aug 14, 2023	BUY	$22.62 - $39.32 $1.24 Million - $2.15 Million	54,600 Added 142.19%	93,000 $2.36 Million
Q1 2023 May 15, 2023	BUY	$30.17 - $41.11 $21,119 - $28,777	700 Added 1.86%	38,400 $1.39 Million
Q4 2022 Feb 14, 2023	SELL	$36.43 - $49.4 $947,180 - $1.28 Million	-26,000 Reduced 40.82%	37,700 $1.49 Million
Q3 2022 Nov 14, 2022	SELL	$40.66 - $53.03 $81,320 - $106,060	-2,000 Reduced 3.04%	63,700 $2.97 Million

151

39.3M

67.9K

1.59M

Ticker NVRO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 35,387,800
Market Cap $134M
Description
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.